A novel cancer vaccine for melanoma based on an approved vaccine against measles, mumps, and rubella.
PeptiENV
Priorix
cancer vaccines
measles
mumps
oncolytic viruses
personalized medicine
rubella
Journal
Molecular therapy oncolytics
ISSN: 2372-7705
Titre abrégé: Mol Ther Oncolytics
Pays: United States
ID NLM: 101666776
Informations de publication
Date de publication:
16 Jun 2022
16 Jun 2022
Historique:
received:
09
06
2021
accepted:
14
04
2022
entrez:
16
5
2022
pubmed:
17
5
2022
medline:
17
5
2022
Statut:
epublish
Résumé
Common vaccines for infectious diseases have been repurposed as cancer immunotherapies. The intratumoral administration of these repurposed vaccines can induce immune cell infiltration into the treated tumor. Here, we have used an approved trivalent live attenuated measles, mumps, and rubella (MMR) vaccine in our previously developed PeptiENV cancer vaccine platform. The intratumoral administration of this novel MMR-containing PeptiENV cancer vaccine significantly increased both intratumoral as well as systemic tumor-specific T cell responses. In addition, PeptiENV therapy, in combination with immune checkpoint inhibitor therapy, improved tumor growth control and survival as well as increased the number of mice responsive to immune checkpoint inhibitor therapy. Importantly, mice pre-vaccinated with the MMR vaccine responded equally well, if not better, to the PeptiENV therapy, indicating that pre-existing immunity against the MMR vaccine viruses does not compromise the use of this novel cancer vaccine platform.
Identifiants
pubmed: 35572195
doi: 10.1016/j.omto.2022.04.002
pii: S2372-7705(22)00054-7
pmc: PMC9065466
doi:
Types de publication
Journal Article
Langues
eng
Pagination
137-145Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
Vincenzo Cerullo is a co-founder and shareholder at VALO therapeutics.
Références
J Immunother Cancer. 2020 Feb;8(1):
pubmed: 32102830
Cancer Cell. 2020 Apr 13;37(4):443-455
pubmed: 32289269
Cancer Invest. 2018 Feb 7;36(2):106-117
pubmed: 29485292
Proc Natl Acad Sci U S A. 2020 Jan 14;117(2):1119-1128
pubmed: 31888983
J Immunogenet. 1989 Aug-Oct;16(4-5):291-303
pubmed: 2639904
EMBO Mol Med. 2020 Jan 9;12(1):e10375
pubmed: 31746149
Mol Ther. 2018 Sep 5;26(9):2315-2325
pubmed: 30005865
Br J Cancer. 2018 Jan;118(1):9-16
pubmed: 29319049
Oncoimmunology. 2018 May 7;7(8):e1457596
pubmed: 30221051
Adv Protein Chem. 2003;64:363-77
pubmed: 13677053
Proc Natl Acad Sci U S A. 2011 Oct 4;108(40):16723-8
pubmed: 21933959
Med (N Y). 2021 Sep 10;2(9):1050-1071.e7
pubmed: 34414383
Clin Cancer Res. 2013 Oct 1;19(19):5300-9
pubmed: 24089443
BMC Bioinformatics. 2021 Mar 26;22(1):163
pubmed: 33771096
Signal Transduct Target Ther. 2020 Jul 2;5(1):113
pubmed: 32616710
Curr Pharm Biotechnol. 2012 Jul;13(9):1732-41
pubmed: 21740361
mBio. 2021 Feb 2;12(1):
pubmed: 33531391
Cancer. 2010 Apr 1;116(7):1767-75
pubmed: 20143434
Hum Vaccin Immunother. 2020 Sep 1;16(9):2217-2218
pubmed: 32501133
Cell. 1988 Sep 9;54(6):777-85
pubmed: 3261634
Sci Transl Med. 2019 Oct 23;11(515):
pubmed: 31645452